Redhill Biopharma (RDHL)

• Market cap: $4.23M
• 1 day: -2.31%
• 5 days: -19.11%
• 1 month: -33.16%
• 3 months: 4.96%
• 6 months: -39.52%
• Year to date: -80.16%
• 1 year: -84.03%
• 5 years: -99.98%
• 10 years: -99.99%
• Sector: Healthcare
• Industry: Drug Manufacturers - Specialty & Generic

About: Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.

Employees: 35